Antihypertensive combination of valsartan and a calcium channel blocker
CA 2678722 C · Owner: Novartis Ag · Inventors: De Gasparo, Marc; Webb, Randy Lee
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a method for the treatment or prevention of a condition or disease selected from the group consisting of hypertension (acute and chronic) congestive heart failure left ventricular dysfunction and hypertrophic cardiomyopathy myocardial infarction and its sequelae supraventricular and ventricular arrhythmias atrial fibrillation or atrial flutter, atherosclerosis angina (whether stable or unstable), renal insufficiency (diabetic and non-diabetic) heart failure, angina pectoris, diabetes hypertension in patients with NIDDM, secondary aldosteronism primary and secondary pulmonary hyperaldosteronism primary and pulmonary hypertension, renal failure conditions such as …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 1999 and granted August 27, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 9, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.